Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the period ending January 27, 2026. The report primarily addresses corporate governance matters, specifically the scheduling of a Special General Meeting of Shareholders and a recent notice of non-compliance regarding audit committee composition received from the NYSE American Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural report regarding shareholder meetings and regulatory compliance rather than a financial statement.
Material Changes
- Audit Committee Non-Compliance: On January 21, 2026, the Company received a notice from the NYSE American indicating non-compliance with Section 803(B)(2)(a) of the Company Guide. The audit committee no longer consists of at least three independent members following the resignation of an independent director announced on January 16, 2026.
- Listing Status: The notice had no immediate effect on the listing or trading of the Company's American Depository Shares (ADSs), which continue to trade under the symbol "CANF."
Guidance, Outlook, and Risks
Special General Meeting: The Company will hold a Special General Meeting on March 3, 2026, at 3:00 p.m. Israel time. The agenda includes the proposed election of a new independent director expected to join the audit committee to restore compliance.
Compliance Timeline: The Company has until the earlier of its next annual meeting of shareholders or January 14, 2027 (or July 13, 2026, if the annual meeting occurs before that date) to regain compliance with audit committee requirements.
Risks: The primary risk identified is the potential loss of listing status if the Company fails to reconstitute its audit committee within the specified grace period.
Key Facts for Investor Verification
- Verify the outcome of the Special General Meeting scheduled for March 3, 2026, specifically the election of the new independent director.
- Confirm the Company's status regarding NYSE American audit committee compliance after the March 3, 2026 meeting.
- Review the resignation details of the previous independent director announced on January 16, 2026, to understand the governance gap.